+63.9%
HAL vs MRNA
+485.7%
-421.8%
-27.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.6% | +5.4% | -6.0% | -0.6% |
| 7D | -3.3% | -1.1% | -2.2% | -3.3% |
| 30D | +8.2% | +126.1% | -118.0% | +7.6% |
| 3M | -9.4% | +190.0% | -199.5% | -10.8% |
| 6M | +0.6% | +157.2% | -156.6% | -0.4% |
| YTD | +28.6% | +388.2% | -359.6% | +23.7% |
| 1Y | +63.9% | +467.0% | -403.1% | +58.5% |
| All | +63.9% | +485.7% | -421.8% | +58.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling